Ethyl 3-oxo-2-[4-(trifluoromethyl)phenoxy]butyrate, 95.0%, 5g

2,2-Dimethyl-2,3-dihydro-1h-inden-1-ol, 97%, 250mg

tert-Butyl 6-hydroxy-6-methyl-2-azaspiro[3.3]heptane-2-carboxylate, 98%, 250mg

Soluzione ammoniacale 20%, 20%, pura, 5 l, confezione plastica.

2-(4-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 10g

3-Methylpyridine-2,6-diamine, 95.0%, 5g

3-(4-oxo-1,4-dihydroquinazolin-2-yl)phenyl acetate, 97%, 250mg

(S)-2-((tert-Butoxycarbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid, 97%, 100mg

[5-(3-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-acetic acid ethyl ester, 95.0%, 1g

1-(3-Ethynyl-2-fluorophenyl)ethan-1-one, 1g

3-iodo-1-propanol acetate, 95%, 25g

1-Bromo-3-[(2-methylpropoxy)methyl]benzene, 95%, 1g

Diapositiva a contrasto di fase con fasatura per obiettivi di fase piano PLPH 10x e S40x